Table IV.
Non-susceptible percentages* of Gram-positive cocci isolated from all specimen
| Antimicrobial agent | S. aureus | MSSA | MRSA | CoNS | E. faecalis | E. faecium |
|---|---|---|---|---|---|---|
| Cefoxitin | 35.3 | 0 | 99.9 | 68.9 | - | - |
| Ciprofloxacin | 78.8 | 72.7 | 89.9 | 58.3 | 87.6 | 94.6 |
| Clindamycin | 23.6 | 14 | 40.3 | 43.6 | - | - |
| Erythromycin | 53.2 | 41.2 | 74.6 | 74.6 | - | - |
| Linezolid | 0.8 | 0.3 | 1.6 | 2.2 | 1.7 | 4.8 |
| Mupirocin/gentamicin (high level)† | 2.2 | 1.2 | 4.6 | - | 47.7 | 72.2 |
| Penicillin/ampicillin† | 92.8 | 89.3 | 98.9 | 85.4 | 30.2 | 79.6 |
| Teicoplanin | 1.4 | 0.6 | 2.6 | 3.4 | 4.2 | 20.8 |
| Tetracycline | 10.9 | 7.3 | 17.5 | 18.5 | - | - |
| Tigecycline | 0.6 | 0.2 | 1.2 | 2.1 | - | - |
| Trimethoprim-sulphamethoxazole | 35.5 | 31.2 | 43.4 | 53.2 | - | - |
| Vancomycin | 1.5 | 0.5 | 3.8 | 2.3 | 3.9 | 22.1 |
*Non-susceptibility data include both I and R data, †Mupirocin and penicillin tested for S. aureus, MSSA, MRSA, CoNS. Gentamicin and ampicillin tested for E. faecalis and E. faecium. S. aureus, Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; CoNS, coagulase-negative Staphylococcus aureus; E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; I, intermediate; R, resistant
Source: ICMR-AMRSN data 2016-2018